Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07039942

French Prospective Multicentric Study in Real World

Omnipod 5 - A French Prospective Multicentric Study in Real World

Status
Recruiting
Phase
Study type
Observational
Enrollment
304 (estimated)
Sponsor
Insulet Corporation · Industry
Sex
All
Age
2 Years
Healthy volunteers
Not accepted

Summary

The purpose of this postmarket clinical investigation is to evaluate the levels of glycemic control, quality of life, and satisfaction, as well as the patient experience, and acute diabetes complication rates provided by the Omnipod 5 Automated Insulin Delivery System (referred to as the Omnipod 5 System) in a real-world setting.

Detailed description

Twelve-month, real-world, non-interventional, prospective follow-up of adult and pediatric patients aged more than 2 years old, prescribed one of the Dexcom (Dexcom G6 or G7) configurations commercially available of the Omnipod 5 Automated Insulin Delivery System in France. OPTIMAL-A study (Omnipod 5 - A French Prospective Multicentric Study in Real World), aims to provide the requisite real-world data on the glycemic control, quality of life, safety, and device usage profiles of users of the Omnipod 5 System during the 12 months after starting using Omnipod 5 in automated mode.

Conditions

Interventions

TypeNameDescription
DEVICEOmnipod 5The Omnipod 5 Automated Insulin Delivery System (Omnipod 5 System) is a tubeless insulin pump with a mono-hormonal insulin delivery system designed to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in people aged 2 years and older who require insulin. The Omnipod 5 System is intended to function as an automated insulin delivery system when used with compatible Continuous Glucose Monitoring (CGM) systems.

Timeline

Start date
2025-07-23
Primary completion
2027-05-01
Completion
2027-05-01
First posted
2025-06-26
Last updated
2026-04-09

Locations

24 sites across 1 country: France

Regulatory

Source: ClinicalTrials.gov record NCT07039942. Inclusion in this directory is not an endorsement.